Search Results - "Pungor, K"

HSD14 X-Linked Retinitis Pigmentosa Impacts Patients’ Independence, Work Status, and Quality of Life: Insights from the Cross-Sectional Explore Xlrp-1.2 Physician Survey by Denee, T., Lee, J.M., Fartaes, A., Ampeh, K., Pungor, K.

Get full text

HSD119 Patient Pathways, Genetic Testing, and Diagnosis of X-Linked Retinitis Pigmentosa in Europe: Insights from the Cross-Sectional Explore Xlrp-1.2 Physician Survey by Denee, T., Lee, J.M., Fartaes, A., Ampeh, K., Pungor, K.

Get full text

HSD42 The Humanistic Impact of X-Linked Retinitis Pigmentosa (XLRP): Results from the Explore Xlrp-2 Retrospective Chart Review and Cross-Sectional Survey of Patients and Caregivers in 10 Countries by Denee, T., Lahaye, M., van Denderen, J., Lee, J., Pungor, K.

Get full text

P.391 Patient, investigator, nurse, carer questionnaire: exploring the impact of less frequent medication administration in the maintenance treatment of schizophrenia by Lahaye, M., Marsella, C., Matthew, I., Pungor, K., Wooller, A.

Get full text

Factors and their weight in reducing life expectancy in schizophrenia by Correll, Christoph U., Bitter, István, Hoti, Fabian, Mehtälä, Juha, Wooller, Annette, Pungor, Katalin, Tiihonen, Jari

“…Schizophrenia is associated with a wide range of socioeconomic and health-related problems, as well as 10–25 potential life-years lost. While lifestyle…”
Get full text

POSB236 X-Linked Retinitis Pigmentosa Negatively Affects Patients’ Work Status, Independence, and Quality of Life: Results from the Cross-Sectional EXPLORE XLRP 1 Physician Survey by Lee, J, Pungor, K, Kambarov, Y, Nissinen, R, Denee, T, Ampeh, K, Parmeggiani, F

Get full text

POSA249 Diagnostic Pathways, Genetic Testing, and Impact of COVID-19 on Patients in Europe with X-Linked Retinitis Pigmentosa: Results from the Cross-Sectional Explore XLRP 1 Physician Survey by Denee, T, Pungor, K, Kambarov, Y, Nissinen, R, Lee, J, Ampeh, K, Parmeggiani, F

Get full text

Improvement of negative symptoms in schizophrenia with paliperidone palmitate: 1-month versus 3-month long-acting injectables by Mathews, M., Gopal, S., Singh, A., Gogate, J., Kim, E., Pungor, K.

Get full text

F110. SYMPTOMATIC REMISSION WITH PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA PATIENTS IN A CLINICAL PRACTICE SETTING by Garcia-Portilla, M P, Llorca, P M, Maina, G, Bozikas, V P, Devrimci-Ozguven, H, Kim, S W, Bergmans, P, Usankova, I, Cherubin, P, Najarian, Dean, Pungor, K

“…Abstract Background Symptomatic remission (SR) is an important outcome for schizophrenia patients [1]. In pivotal trials, paliperidone 3-monthly formulation…”
Get full text

Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: functioning and resource use by Garcia-Portilla, P., Llorca, P.M., Maina, G., Bozikas, V.P., Devrimci-Ozguven, H., Kim, S.W., Bergmans, P., Usankova, I., Cherubin, P., Pungor, K.

Get full text

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis by Li, Gang, Keenan, Alexander, Daskiran, Mehmet, Mathews, Maju, Nuamah, Isaac, Orman, Camille, Joshi, Kruti, Singh, Arun, Godet, Annabelle, Pungor, Katalin, Gopal, Srihari

“…Relapse and treatment adherence to paliperidone palmitate once-monthly (PP1M) and three-monthly (PP3M) formulations in patients with schizophrenia were…”
Get full text

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies by Mathews, Maju, Gopal, Srihari, Singh, Arun, Nuamah, Isaac, Pungor, Katalin, Tan, Wilson, Soares, Bernardo, Kim, Edward, Savitz, Adam J

“…Sudden discontinuation from antipsychotic treatment is a common occurrence in patients with schizophrenia. Lower rates of relapse could be expected for…”
Get full text

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study by Gopal, Srihari, Gogate, Jagadish, Pungor, Katalin, Kim, Edward, Singh, Arun, Mathews, Maju

“…Negative symptoms in schizophrenia are associated with impairments in social and cognitive functioning leading to substantial long-term disability. Available…”
Get full text

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia by Lambert, Martin, Sanchez, Pedro, Bergmans, Paul, Gopal, Srihari, Mathews, Maju, Wooller, Annette, Pungor, Katalin

“…This pragmatic clinical study aimed to assess goal attainment among patients with schizophrenia treated with paliperidone palmitate 3-monthly (PP3M) and its…”
Get full text

Electrochemical calibration of in vivo brain dialysis samplers by Juhasz, G, Tarcali, J, Pungor, K, Pungor, E

“…Measurement of state-related changes in the concentration of an endogenous substance using the in vivo dialysis technique requires a definition of the factors…”
Get more information

Paradoxical sleep deprivatory effect of a single low dose of MPTP which did not produce dopaminergic cell loss by PUNGOR, K, HAJNAL, A, KEKESI, K. A, JUHASZ, G

“…In a previous study, we reported on a selective and long-lasting paradoxical sleep (PS) deprivation in cats following repeated administration of the Parkinson…”
Get full text

Single low dose of MPTP decreases extracellular levels of noradrenaline and monoamine metabolites in the ventrobasal thalamus of the rats by Nyitrai, G, Kékesi, K A, Dobolyi, A, Pungor, K, Juhász, G

“…A single low dose of the neurotoxin: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) results paradoxical sleep deprivation and reduction in food intake…”
Get more information

A novel effect of MPTP: the selective suppression of paradoxical sleep in cats by Pungor, K, Papp, M, Kékesi, K, Juhász, G

“…We studied the effect of MPTP on sleep-wakefulness cycle in cats. Five mg/kg n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was administered i.p. for 5…”
Get more information

Local perfusion of the thalamus with GABA increases sleep and induces long-lasting inhibition of somatosensory event-related potentials in cats by Juhász, G, Emri, Z, Kékesi, K, Pungor, K

“…The extracellular concentration of gamma-aminobutyric acid (GABA) was increased in the ventroposterolateral nucleus of the thalamus in cats using in vivo…”
Get more information